Global News

Caligor appoints Andrea Chopek and Craig LaMarca to Clinical Trial Services Business Unit

Monday, February 13, 2017

Caligor Opco, which specializes in global comparator sourcing, early access to medicines and drug life-cycle management, has named two pharmaceutical executives to its Clinical Trial Services (CTS) business unit. Andrea Chopek has been appointed global head of Business Development for CTS. Craig LaMarca has been named global head of Business Development for TrialAssist, a business line under CTS. Both positions are new for the company, which recently expanded its international operations with the opening of a state-of-the-art, 33,000-square-foot facility in the UK.

[Read More]

TRACON Pharma releases TRC105 phase II results for recurrent glioblastoma

Monday, February 13, 2017

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, has reported top-line results from a randomized phase II clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). 

[Read More]

Changes in recruitment

Monday, February 13, 2017

The Pulse on Patient Recruitment by Ashley Tointon

Looking retrospectively, patient recruitment activities have evolved greatly. Unfortunately, some issues are cyclical and see resurgence from time to time. Sending in-person recruitment assistance to sites, leveraging patient advocacy outreach and the increased use of videos are just a few examples of valuable tactics that come in and out of popularity, much like recycled fashion. Is this because we don’t disseminate learning? Is it because we run out of new ideas to solve old issues? Realistically, there are many old patient recruitment problems that have yet to be properly solved. Two major issues yet to be solved are the awareness of clinical trials and how to engage with patients.

[Read More]

GeNeuro, NIH partner to develop novel antibody treatment for ALS

Friday, February 10, 2017

GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), has announced the signing of a Cooperative Research and Development Agreement (CRADA) with The National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). The research will evaluate the ability of these antibodies to neutralise a potential causal factor of ALS, the envelope protein of HERV-K (a family of Human Endogenous Retroviruses, HERVs). 

[Read More]